Job title: Senior Principal Scientist
Phil Brandish trained in chemistry and biochemistry and has almost 20 years of experience in drug R&D and has focused now for several years on cancer immunotherapy. Phil leads a team of immunologists and cell biologists at Merck Research Labs in Boston focused on myeloid and fibroblast biology for the treatment of cancer. Phil serves as co-lead for several early clinical stage immuno-oncology programs as well as subject matter expert for partnership and licensing opportunities.
Therapeutic Approaches & Basic Research on Myeloid Immune Suppression in the Tumor Microenvironment 3:30 pm
• Analyze the evidence for myeloid cell infiltrates limiting clinical responses • Discuss the types and mechanisms of myeloid immune suppression in the TME • Outline emerging therapeutic approaches and basic researchRead more
day: Day One